SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?


To: Montana Wildhack who wrote (6941)3/14/2001 3:36:35 AM
From: Tom Gordon  Read Replies (1) | Respond to of 14101
 
Gentlemen,

Rebecca sure is exuding rational exuberence these days.
The excitement in ramping up this product, and the possibilities of others just has to be killing her because of the oath of secrecy.
Might suggest we here on this thread hire a PI to follow her around to further confirm this. <<LOL>>

Her reference to facility expansion sure spells it out.
Deals are on the threshold and many Pharma's slipping around in there salivation trying to get a piece of the action.
Wolf a question, would Provalis have the capability of producing Pennsaid in the UK for EU distribution or am I way off base here?

Regards TG.



To: Montana Wildhack who wrote (6941)3/14/2001 6:06:46 AM
From: Mark Bartlett  Read Replies (2) | Respond to of 14101
 
Wolf,

<<Has OXO filed for Canada? If not why isn't that a priority
for Dimethaid given the phase III is in both countries?>>

Until the phase III trials are done and analyzed, I do not see any reason for DMX to file a NDS. I certainly hope they do file a NDS for approval in Canada, once the results are known.

Obviously they took the time to get approval for the phase III trials here, so I expect that is part of their game plan.

MB